The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy

Journal of Viral Hepatitis

Volumn 20, Issue 9, 2013, Pages 645-649

  Liu, H L ^a   Zhao, Z ^a   Yang, H ^a   Liu, F F ^a   Liu, Q ^b   Luo, Q ^a   Yuan, Q ^a   Chen, L M ^c,d   Zeng, A Z ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE OF BLOOD TRANSFUSION   (China)

Author keywords

HBV activation; immunosuppressive treatment; nucleoside analogue; occult HBV infection; prophylactic treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; AMINOPTERIN; AZATHIOPRINE; CORTICOSTEROID; CORTISONE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; METHOTREXATE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RISK REDUCTION; SEROCONVERSION; TREATMENT DURATION; TREATMENT REFUSAL; VIRUS ACTIVATION;

HBV ACTIVATION; IMMUNOSUPPRESSIVE TREATMENT; NUCLEOSIDE ANALOGUE; OCCULT HBV INFECTION; PROPHYLACTIC TREATMENT;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHEMOPREVENTION; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NUCLEOSIDES; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84881474420     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12087     Document Type: Article

References (9)

1. Hui CK, Sun J, Au WY,. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42 (06): 813-819.
2. Coppola N, Tonziello G, Pisaturo M, et al,. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol 2011; 83: 1909-1916.
3. Palmore TN, Shah NL, Loomba R, et al,. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppressive. Clin Gastroenterol Hepatol 2009; 7: 1130-1137.
4. Wong DK, Huang FY, Lai CL, et al,. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54: 829-836.
5. Raimondo G, Navarra G, Mondello S, et al,. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008; 48: 743-746.
6. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ,. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978; 298 (25): 1379-1383.
7. Kim JJ, Bae SC, Sung YK, et al,. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-α blocker in the treatment of rheumatic diseases. J Rheumatol 2010; 37 (2): 346-350.
8. Hsu C, Hsiung CA, Su IJ, et al,. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in Non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47 (3): 844-853.
9. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST,. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010; 116 (1): 115-121.